In this blog, we speak to Jana about Navignostics’ mission, and how the team plans to revolutionise personalised oncology treatments with the help of data and AI.
Navignostics is a start-up personalised cancer diagnostics business based in Zurich, Switzerland. Our goal is simple – we want to revolutionise cancer treatment by identifying a highly personalized and thus optimal treatment for every patient, to ensure that each patient’s specific cancer is targeted and fought as needed. Our capabilities allow us to do this by analysing tumour material, through extracting spatial single-cell proteomics information. and using this data to analyse many proteins simultaneously in individual cells within the tissue.
Single-cell proteomics comprises of measuring and identifying proteins within a single cell, whereas spatial proteomics focuses on the organisation and visualisation of these proteins within and across cells. Combining these two research tools allows the team at Navignostics to characterise tumours on a cellular level, by identifying the proteins present across cells in a tumour, and also how these proteins and cells are organised. This means that the team can provide a more accurate estimate for how certain tumours will respond to different medications and treatments.
Proteins are typically the target of cancer drugs and measuring them on a cellular level allows us to identify different types of tumour cells, as well as immune cells that are present and how the two interact. This data is highly relevant to inform clinicians of the best form of (immuno-) oncology and combinatorial treatment for individual patients. Also, this information is highly relevant to pharma companies in order to accelerate their oncology drug development, by providing insight on drug mode of action, and signatures to identify responders to novel drugs.
The kind of data that we are able to extract from different types of tumours are monumentally valuable, so the work doesn’t stop there. All of the data we harness from these tumours is stored centrally, and we plan on utilising this data by building it into a system we refer to as the Digital Tumour, that will continuously allow us to improve the recommendations we can make to our clinical and pharma partners. Our journey has been rapid, though it is built on years of research and preparation: we founded the business in 2022, as a spin-off from the Bodenmiller Lab at the University of Zurich.
The dream became a reality for us in November 2022, when we secured a seed investment of 7.5m CHF. This seed funding will allow us to pursue our initial goals of establishing the company, achieving certification for our first diagnostic product and developing our Digital Tumour. By extension, collaborating with pharma and biotech partners in oncology drug development. It has also given us the resource we need to move to our own premises. We are due to move off university campus in May 2023. This offers us great opportunity to push forward with the certification processes for our new lab, and it gives us to the chance to grow our team and expand our operation. We will be located in a start-up campus for life science organisations in the region of Zurich, so we’ll be surrounded by companies operating in a similar field and at a similar capacity.
The Digital Tumour will be the accumulation of all the molecular data we have extracted from every tumour that we have analysed to date, and ongoing. Connected to that, we store information on the clinical parameters and patient response to treatment. Over time, our aim is to utilize this central data repository to identify new tumour signatures, and build a self-learning system that will provide fully automated treatment suggestions for new patients, based on how their molecular properties compare to previously analysed patients that have been successfully treated.
Our data storage is quite advanced, so volume isn’t really a challenge for us. Our main focus is standardising the input of data itself. The technology is based on years of research and the data analysis requires a great deal of experience and in-depth expertise. In order to extract the full value from this data, it must be completely standardised. Data integrity is therefore vital to our work, and allows us to get the maximum value from past analyses. Our past experience in the Bodenmiller Lab allowed us to develop standardised processes to ensure that all of our data is fully comparable, which means that we can learn more and more from our past data, and apply this to new cases that we analyse.
It is also important to report on our complex data in a comprehensive but easily interpretable manner to the clinician/tumour board who needs to organise a treatment plan. We’re currently working with our clinical collaborators to develop readily understandable and concise reporting outputs. Unlike genomics analysis, our reports focus on proteins in tissue, which is the same information that clinicians are used to working with. So, there is a common language there that offers us the unique opportunity to provide clinicians with data they can easily interpret and work with.
It’s important to note that personalised treatment approaches and precision medicine are not new concepts in the diagnostics space. However, our technology and algorithms allow us to extract novel types of biomarkers which were previously inaccessible or unknown, so we’re helping to level up the playing field and give clinicians and drug developers’ comprehensive information to individualize therapies.
Comprehensive tumour data is truly at the heart of what we do, and one key benefit of our technology is that we’re able to analyse very small amounts of sample – such as fine needle biopsies – to provide therapy suggestions. We can also analyse bio banked tumour material, so if there is any old material that has been stored, we have the ability to analyse those samples retrospectively. Not only does this help us to fuel our Digital Tumour with more data, but it also allows us to examine new fields such as long-term survival rates of patients with these tumours. This is of huge value to fuel our product development pipeline because it allows us to identify different molecular properties between individuals that may not have been considered on a clinical level, but may have played a role in patient responses to treatments and survival outcomes in the long-term.
This kind of retrospective data also plays a key role in the evolution of healthcare and drug development, as having the technologies available to acquire this sort of data and mine it to our advantage will provide enormous benefits. These include improving individual treatment courses for patients, as well as expediting the development of novel cancer drugs so pharma companies can get more effective treatments to market sooner.
For example, one commonly cited statistic is that 90% of clinical drug development fails during phase I, II, III trials and drug approval. Often, this may arise from a lack of available information to identify the subset of patients most likely to benefit from a novel drug. Having access to Navignostics’ technology and algorithms and a database such as the Digital Tumour will offer the potential to pre-select the right patients to enroll in clinical trials, and more easily identify the patients that do respond to the novel treatment, which could substantially expedite the speed of drug development in the trial stage, and help bring more effective drugs to the market.
Even unsuccessful trials offer valuable opportunities: it is possible to repurpose and reanalyse material from previous failed trials. Such high rates of failure in clinical development means that there are a large number of companies that have invested $millions in developing drugs that have not come to fruition, so if companies want to re-mine their data, our team can reinterpret the existing work into identifying more successful strategies, so we can give those drugs another chance and offer a better chance of Return on Investment.
A failure no longer needs to be a failure. Navignostics and its offerings can bring value to our pharma and biotech partners, and will also bring direct benefit to patients and clinicians once we launch our diagnostics product. So, data from every facet of the oncology industry, from curing a patient to halting the development of a drug, can offer us valuable insight that both we and the Digital Tumour could learn from when developing treatments.
The next three years will be critical for our work, and we have projected timelines and key milestones for our diagnostics developments that we will achieve until our next funding round. Along the way, we are actively speaking to biotech and pharmaceutical organisations to identify projects and build the foundation for long lasting collaborations. We are looking forward to a successful continuation of the Navignostics development in 2023!
Scimcon is proud to showcase start-up companies like Navignostics, and we’re looking forward to seeing how the company will grow over the coming years.
To contribute to our industry leader blog series, or to find out more about how Scimcon supports organisation with lab informatics and data management solutions, contact us today.
Scimcon continues to meet the criteria for Carbon Neutral Britain for a second time in 2022. This has been attained through conducting the required measuring, calculating, and offsetting carbon emissions between the period of June 2021 and May 2022.
After first receiving the initial award in 2021, we are proud to have maintained this title throughout the following year, underpinning Scimcon’s global commitment to a sustainable future.
Co-founder of Scimcon Geoff Parker recognises the global nature of the company after first obtaining the award in 2021; “Our customer base consists of a diverse range of lab-centric organisations including large pharma and biopharma companies internationally. As Scimcon sees further expansion and more on-site projects in 2022, we are keen to drive our sustainability initiative through the global projects taking place all over the world. Carbon Neutral Britain pledged to offset our remaining carbon usage with accredited global projects that reduce the amount of CO2 in the earth’s atmosphere. After gauging the environmental impact of our operations, we knew this would be a priority of ours moving forward.”
We renewed our Carbon Neutral Britain certification by offsetting against four international projects set up by our awarding sponsor. The Burgos Wind Project is the largest wind farm in the Philippines. This project produces clean energy, omitting sources that contribute pollutants and greenhouse gas emissions to the environment. Also, the Rice Husk Power Project, the first renewable energy scheme to utilize rice husk as biomass fuel for electricity generation in Cambodia. Not forgetting the remaining two projects, the Andes Mountains Hydro Power in Chile, and the Huaneng Changyi Wind Farm Project. All equally as impactful, we recognise that offsetting our carbon usage against projects like these is vital for our own global strategy here at Scimcon.
As we continue to operate in the complex lab informatics field, Scimcon’s efforts to reduce carbon emissions must continue to benefit our customers. Scimcon will continue to responsibly balance the very real need for on-site client interaction with the use of innovative communications, thereby reducing the impact of unnecessary travel. If taking part in auditory assessments and remediations like this one offsets our necessary emissions and contributes to a more sustainable future, the Scimcon team is more than dedicated to its requirements.
For more information about how we originally achieved our certification, visit our blog. To learn how Scimcon can help support your business with its IS strategy, contact us.Scimcon Sponsors Oxford Global’s SmartLabs UK?
SmartLabs UK is just days away from taking place in the capital of the country, and we’re proud to be sponsoring the 4th Annual SmartLabs Congress 2022 in London this year. Here, we explore what the two-day event will entail.
On the 8th and 9th September 2022, the Novotel London West will open its doors in welcoming leading experts of the lab informatics field to educate, inform and excite. From technical presentations to think-tank roundtable discussions, we had to join in.
Within a post-pandemic society, our reliance upon digital technology is greater than ever. In the field of life sciences, lab scientists are seeking better ways of consolidating and storing data. While paper-based labs are largely a thing of the past, many are filled with isolated information systems and nonstructured approaches, such as experimental workflows based at least partly in Excel.
Not only do such environments risk human error in transcription and duplication they restrict the organisations’ ability to search and mine data for critical insights.
Removing these disjointed workflows and dataflows are a key part of the wider digitalisation processes which are taking place throughout the lab space. It is no longer enough for laboratories to solely rely on LIMS, ELN, SDMS and instrument data systems.
It is important for the Scimcon team to stay ahead of the zeitgeist from customer-to-customer. Keeping up to date with current trends in lab informatics is at the heart of what we do.
What has this got to do with Oxford Global’s SmartLabs UK? The event will be split into two easy-to-follow streams, featuring all things lab informatics. If you’re unsure of what the latest innovations are, SmartLabs UK will provide the latest updates via over 50 cutting-edge presentations and a series of interactive discussions.
With virtual events becoming the norm in recent years, it is exciting for attendees to be given the opportunity of an in-person, collaborative experience. Day one of Oxford Global’s SmartLabs UK involves the exploration of monitoring and operational tools, and virtual reality tech demonstrations. Day two will delve into data standardisation and governance in lab informatics, and this is just the beginning. Some of the confirmed leading experts attending the event include the Genentech Director, Erik Bierwagen and Goldsmiths University professor, Larisa Soldatova.
If you think you’ve heard all of the latest informatics tools and technologies that are available, one of the benefits of attending SmartLabs UK will be the advice given on how to use these systems to leverage your data. After all, it is vital to understand how to put theory into practice. Taking advantage of the event’s opportunity for interaction, the 4th annual congress will provide an Event App. This will allow attendees to watch selected presentations on-demand, and contains extensive networking features. The benefits of using the app include; a dynamic agenda in which you will receive notifications of any changes to the day, a chance to the view the profiles of all speakers and organisations and a personalisation tool that allows you to organise and plan your schedule. There will also be an Event App prize draw for those participating in specified activities throughout the event.
As programme sponsor of Oxford Global’s SmartLabs UK, we are thrilled to assist in paving the way to laboratory digitalisation through automation, cutting-edge informatics tools and technologies. We believe that the digitisation of your laboratory projects should be done with the best advice and trusted expertise behind you. In turn, this is vital for the healthy reproduction of the life sciences industry.
Throughout the event, you can expect to receive this information in an engaging, illuminating way and through a variety of mediums. We will help to deliver think-tank discussions as well as trusted, face-to-face conversations with our team members who have direct lab experience. For those who prefer independent research and networking, we support the use of the Event App for all your lab informatics queries.
To organise a meeting with our team at the event, or to learn more about how Scimcon can support your digital lab transformation, contact us today. To learn more about lab informatics read more on our blogs via our website.What can we expect from Lab of the Future??
With the March congress on the horizon, we take a look at some of the trends within the industry over the last year, and what to expect from the March event.
It’s not a surprise that, with the impact of the pandemic, the importance of digitisation has been heavily reinforced. In early 2020, we reflected on Scimcon’s experience of providing remote support to clients and some of the changes we witnessed as a result of the COVID-19 pandemic, and now almost two years on, we’re seeing a new way of working across labs and organisations.
With digital transformation hot on the global agenda, what’s next for analytical and clinical laboratories? What will the lab of the future look like? Lab of the Future’s March congress aims to answer that question.
With a selection of activities scheduled across the 2-day event, there is no shortage of opportunity for attendees to get involved – whether that’s in-person in the Boston, MA event, or from the comfort of their own workspace via virtual attendance.
The agenda features a range of roundtables and presentations, including plenary sessions, as well as more focussed discussions on specific topics, from the digital lab to the connected innovation lab. The tradeshow will also feature plenty of networking session throughout, allowing individuals to form valuable new connections and learn more about some of the key players and innovation across the industry.
The event also welcomes a wide of speakers presenting and hosting discussions during the 2-day period. With confirmed speakers from GSK, Merck, Pfizer, Boehringer Ingelheim, and Astrazeneca, amongst many others, it’s guaranteed to be an event filled with interesting discussions from some of the organisations that have become household names over the last 24 months.
In addition to discussions, the event is also hosting technology showcases, for leading solution providers to demonstrate some of the latest and most disruptive innovation that they’ve been perfecting behind the scenes. Focussed work tracks also allow attendees to take a more in-depth look at some of the latest technologies and trends in 4 key areas – lab automation, digitalisation, connectivity, and innovation.
Lab of the Future is an insightful event, and one that we look forward to as well as sponsor each year. The in-person aspect of the event will make for a refreshing change following the pandemic restrictions experienced worldwide, but the additional virtual element of the tradeshow means that users around the globe can participate and get involved, regardless of restrictions and concerns surrounding COVID-19 and travel.
However, in addition to the event, the lab of the future is a concept. Our team at Scimcon has over 20 years of experience in laboratory informatics, and with many of our team members having direct lab experience, we can help you get your digitisation and laboratory informatics project off the ground, whilst understanding the questions and concerns faced by scientists every day.
Scimcon is proud to be sponsoring the Lab of the Future March congress, taking place both virtually and in-person at Hilton Back Bay, Boston, MA on 22nd-23rd March 2022. To organise a meeting and to learn more about how Scimcon can take your lab to the future, contact us today.
Outbreaks in recent years, such as SARS, avian flu, and Ebola, in retrospect seem to have been a testing ground for the current COVID-19 lockdown.
During those outbreaks, study sponsors experienced the challenges of managing clinical trials in traditional ways, and many therefore pushed forward their adoption of eClinical platforms to ensure they could still manage their trials in remote locations, while reducing the impact on their project timelines, ensuring their investigators and monitors remained safe, and enabling their subjects to demonstrate compliance.
The traditional process of conducting clinical trials involves face-to-face interaction with subjects, which is proving difficult in the current lockdown. Subjects still need to make visits to clinical study sites to meet with healthcare professionals however the need to take part in lengthy reviews of their paper diaries is removed when using ePRO. By adopting ePRO for subject reporting, it is possible to significantly reduce the need for close face-to-face interaction with subjects and speed up the collection of quality data. In addition study sponsors benefit from a huge reduction in the travel of the onsite monitoring teams as ePRO increases the ability to conduct remote study monitoring.
With ePRO, the reporting and audit trail is also improved, since it is possible to prove that patients respond daily in accordance with the study Protocol (not possible with manual records).
BYOD (Bring your own device) is another consideration. It is recognised by Scimcon that BYOD reduces hardware challenges associated with the shipment of devices, but more importantly in the current situation removing the need for devices to be passed from human to human both within the logistics departments of the vendors and between the investigators and subjects (often ePRO devices are reused between subjects on an individual study). An upcoming post will cover the BYOD topic in more detail,
The regulator’s requirements for Accurate, Legible, Contemporaneous, Original and Attributable (ALCOA) data are achievable with ePRO platforms, where it has always proved difficult to remove doubt with paper-based Patient Reported Outcomes. In paper records, it is far more difficult for instance to prove when information was recorded, whereas in eClinical platforms when and by whom data is entered is automatically recorded, giving more accurate insight. Legiblity issues obviously become an issue of the past with ePRO.
The clinical trials community has been debating the benefits of ePRO for many years, and with the advent of COVID-19 where face-to-face interactions need to be limited, its adoption seems prescient. ePRO is the no-brainer product for now and future trials, both on data quality and in order to reduce concerns of unnecessary social interactions. Scimcon has hands-on experience with global clinical trials projects and is proven with ePRO platforms, doing what we do best: serving the science community with our skilled project teams to manage data projects globally.
Read more about ePRO:
With 91 million results in google search for the term ‘digital laboratory transformation’, this area seems to be the buzzword of the 20s. Scimcon has long been a stalwart in this area, having provided global partnership in information management to big pharma, bio and clinical organizations for over two decades.
The combined experience of our team spans more than 200 years of hands-on project roles in life sciences! What Information Management projects need, Scimcon has delivered: we have seen every type of project from every type of angle and have a unique perspective on how to ensure success.
And digital laboratory transformation is our lifeblood.
So with the establishment of our new website, we are launching a blog to address the subject of the digital lab and eClinical systems, and try to tackle some of the challenges, whilst also dispelling some of the myths.
Analytical projects including Information System Strategies, LIMS, ELN & LES, SDMS, CDS, DMS, Stability Management and Instrument Integration to mention a few.
Scimcon’s original pedigree lies in the field of Information Management projects in the analytical laboratory. The company and its project consultants have extensive experience in:
With such an extensive knowledge of Information Management in laboratories and life sciences, Scimcon has more recently been invited to supply similar services for the clinical trials industry and especially in the move from paper to digital records. The development and adoption of new Drug Development Tools (DDTs) lies at the intersection between regulatory, science, academia and pharma drug innovation. It is generally thought that paper is a poor format for patient compliance in diaries, and data/ electronic adoption improves both compliance and record-keeping in clinical trials. With our relatable experience, Scimcon has been involved in applying its successful project leadership to the areas of:
Our blogs will help you to navigate the world of outsourcing project leadership for either your analytical or clinical Information Management project.
The first step is to recognize why partnering is helpful:
Successful projects happen when you can trust the partner who is helping you. You do not need to relinquish control of your Information Management projects, but to successfully take them forward a trusted supplier who is not afraid to challenge, and who is vendor-neutral, can bring so much to the table.
In both the largest and the smallest organization alike, the knowledge of the organization rests with its employees. This leads to a natural gap of knowledge between best practice, external and competitor knowledge, and learning from others.
Scimcon fills that gap, its combination of deep hands-on experience, combined with information systems skills, extensive scientific systems and organizational experience, and a commitment to project success, means that we are always committed to bringing successful projects over the line.
We know the shortcuts, we understand the limitations with vendor capabilities, we recognize the scope of your existing systems and we know how to get the best from your teams. And our 100% year-in, year-out experience as a project partner means that we are always working, always able to move projects forward, even when faced with organizational challenges.
Talk to us now, or contact us to discuss your projects, past and future alike.